Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing immuno-oncology product candidates. Its business centers on antibody-based therapies designed to modulate the tumor microenvironment and advance through preclinical and clinical development in cancer indications.

5.06

4.98

— Sensei Biotherapeutics, Inc.
%
Immuno-oncology product candidates70% Antibody-based therapies designed to treat cancer by modulating immune pathways and the tumor microenvironment.
Preclinical research programs20% Discovery-stage programs used to identify and optimize new therapeutic candidates before clinical testing.
Clinical development services10% Activities related to running and supporting clinical trials, regulatory preparation, and data generation.

Sensei does not currently sell approved products; its near-term counterparties are clinical investigators, research...

  • Research and development partnersprimary

    CROs, CMOs, and other vendors that support discovery, manufacturing, and trial execution.

  • Potential collaboration partnersprimary

    Biopharma companies that may license, co-develop, or commercialize product candidates.

  • Clinical investigators and trial sitesprimary

    Hospitals, oncology centers, and investigators that enroll patients and generate clinical data.

  • Future oncology prescriberssecondary

    Physicians and cancer centers that would prescribe approved therapies if programs succeed.

  • Third-party payorssecondary

    Insurers and reimbursement bodies that determine access and pricing for approved products.

The company is headquartered in the United States and conducts its development activities primarily through U.S...

  • •Headquartered and primarily operated in the United States
  • •Clinical and regulatory work is centered on U.S. development programs
  • •May pursue commercialization in the United States and overseas
  • •Relies on third-party vendors that may operate across multiple countries
  • •No product revenue disclosed because no approved products are sold

Sensei’s strategy is to advance its oncology pipeline through preclinical and clinical development while preserving...

01
Advance the pipeline through clinical developmentmedium-term

Clinical data are the main value driver for a development-stage biotech company.

02
Pursue strategic transactions and collaborationsshort-term

Partnerships can provide capital, development support, and commercialization access.

03
Raise additional capitalshort-term

The company needs funding to support ongoing R&D and public-company costs.

04
Build commercialization readinessmedium-term

If a product is approved, the company must be able to market and distribute it.

Sensei faces the classic risks of a clinical-stage biotech: funding dependence, uncertain trial outcomes, and heavy...

critical

Going concern and financing risk

The company has no product revenue and must fund development through external capital.

Scope
Operating runway and ability to continue as a going concern
Materiality
high
high

Clinical development failure

Drug candidates may not show sufficient safety or efficacy in trials.

Scope
Pipeline value and future approval prospects
Materiality
high
high

Third-party dependence

CROs, CMOs, suppliers, and potential partners are essential to execution.

Scope
Trial timing, manufacturing continuity, and commercialization
Materiality
high
high

Competitive intensity in oncology

Large pharmaceutical and biotech companies can advance similar therapies faster.

Scope
Market share, partnering leverage, and physician adoption
Materiality
medium
medium

Healthcare pricing and reimbursement pressure

Future products must navigate payor controls, discounts, and access restrictions.

Scope
Commercial pricing and uptake
Materiality
medium
Research and development accruals
Can move quarterly operating expense materially
Stock-based compensation
Affects operating loss and equity dilution
Fair value of marketable securities
Can change reported net loss and cash resources
Going-concern disclosure
Important for interpreting solvency and financing needs

Mosaic ImmunoEngineering Inc.

CPMV · Biological Products, (No Diagnostic Substances)

PDS Biotechnology Corp

PDSB · Pharmaceutical Preparations

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

Sana Biotechnology, Inc.

SANA · Biological Products, (No Diagnostic Substances)

Pasithea Therapeutics Corp.

KTTAW · Pharmaceutical Preparations

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

: 29/04/2026